BofA raised the firm’s price target on Regeneron (REGN) to $575 from $565 and keeps an Underperform rating on the shares. Q4 results were ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition.

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments.

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Regeneron (REGN) came out with quarterly earnings of $12.07 per share, beating the Zacks Consensus Estimate of $11.62 per share. This compares to earnings of $11.86 per share a year ago. These figures ...

In Q4 2024, Freeport-McMoRan Inc. (NYSE ... and boasts a growing portfolio of high-demand copper and nickel assets. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is an American biotechnology ...

NEW YORK — Boeing announced on Thursday that it incurred a bigger than expected fourth-quarter loss, concluding a difficult 2024 in which it struggled with a lengthy labor strike and safety problems.

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...

Adjusted net earnings decreased 11.1% from $5.56 billion in Q4 2023 to $4.95 billion, highlighting ongoing challenges such as litigation related to talc products that weighed heavily on adjusted ...